SON-1010
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Platinum-resistant Ovarian Cancer
Trial Timeline
Sep 15, 2023 → Jan 8, 2026
NCT ID
NCT05756907About SON-1010
SON-1010 is a phase 1/2 stage product being developed by Sonnet BioTherapeutics for Advanced Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT05756907. Target conditions include Advanced Solid Tumor, Platinum-resistant Ovarian Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05756907 | Phase 1/2 | Terminated |
| NCT05352750 | Phase 1 | Active |
Competing Products
20 competing products in Advanced Solid Tumor